Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-05-05
2009-08-18
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S069600, C435S332000, C435S334000, C424S135100, C530S202000, C536S023530
Reexamination Certificate
active
07575923
ABSTRACT:
Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
REFERENCES:
patent: 5239062 (1993-08-01), Blattler et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 7112324 (2006-09-01), Dorken et al.
patent: 2007/0123479 (2007-05-01), Kufer et al.
patent: 195 31 348 (1997-02-01), None
patent: 195 31 348 (1997-02-01), None
patent: 0 505 908 (1992-09-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 95/11922 (1995-05-01), None
patent: WO 96/36360 (1996-11-01), None
Wang et al., Nuc. Acids Res. 27: 4609-4618, 1999.
Kaufman et al, Blood 94: 3178-3184, 1999.
Wigley et al., Reprod Fert Dev 6: 585-588, 1994.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Anderson, et al., G19.4(αCD3) x B43(αCD19) Monoclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells,Blood, vol. 80, No. 11, pp. 2826-2834 (1992).
Bohlen et al., “Treatment of EB-Virus Induced B-Cell LCL in SCID-HU Mice Using CD3XCD19 Bispecific and CD28 Antibodies.”,Proceedings of the American Association for Cancer Research, vol. 35, Mar. 1994, p. 510, XP-002076122, abstract.
Bohlen, et al., “Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies”,Cancer Research, vol. 53, pp. 4310-4314 (1993).
Bohlen, et al.,Blood, 82:1803-12, 1993.
Csoka, et al., “Activation of T Cell Cytotoxicity Against Autologous Common Acute Lymphoblastic Leukemia (cALL) Blasts by CD3 X CD19 Bispecific Antibody”,Leukemia, vol. 10, pp. 1765-1772 (1996).
Davis, et al., “Current Progress in the Gene Therapy of Cancer”,Current Opinion in Oncology, vol. 8, pp. 499-508 (1996).
De Gast, et al., “Clinical Experience with CD3 x CD 19 Bispecific Antibodies in Patients with B Cell Malignancies”,J. Hema., vol. 4, pp. 433-437 (1995).
De Jonge et al., “Bispecific antibody treatment of murine B cell lymphoma.”,Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997.
De Jonge et al., “In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 X Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model,”The Journal of Immunology, vol. 161, pp. 1454-1461, 1998, (Exhibit 5).
De Jonge et al., “Production And Characterization Of Bispecific Single-Chain Antibody Fragments,”Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995, (Exhibit 4).
Edelstein, et al., “Gene Therapy Clinical Trials Worldwide: 1989-2004—An Overview”,J. Gene Med., vol. 6, pp. 597-605 (2004).
Gruber, et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed inEscherichia coli”, J. of Immunology, vol. 152, pp. 5368-5374 (1994).
Haagen, “Performance of CD3 x CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy”,Leukemia and Lymphoma, vol. 19, pp. 381-393 (1995).
Haagen, et al., “Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma”,Blood, vol. 84, No. pp. 556-563 (1994).
Haagen, et al., “The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2”,Blood, vol. 85, No. 11, pp. 3208-3212 (1995).
Haagen, et al., “Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 X CD19 bispecific antibody to proliferate and become cytotoxic”,Cancer Immunol. Immunother, vol. 39, pp. 391-396 (1994).
Stein, et al., “Die neue WHO-Klassifikation der malignen Lymphome.”, Deutsches Arzteblatt, vol. 96, pp. C-2302-C-2309, Dec. 1999, including English language summary, (Exhibit 2).
Hayden, et al., “Single-chain Mono- and Bispecific Antibody Derivatives with Novel Biological Properties and Antitumour Activity from a COS Cell Transient Expression System”,Therapeutic Immunology, vol. 1, pp. 3-15 (1994).
Holliger, et al., “Diabodies: Small Bispecific Antibody Fragments”,Cancer Immunol. Immunother, vol. 45, pp. 128-130 (1997).
Jonge et al.,Cancer Immunol Immunother45:162-165, 1997.
Kipriyanov, et al. “Rapid Detection of Recombinant Antibody Fragments Directed Against Cell-surface Antigens by Flow Cytometry”,J. of Immunological Methods, vol. 196, pp. 51-62 (1996).
Kipriyanov, et al., “Bispecific CD3 x CD 19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells”,Int. J. Cancer, vol. 77, pp. 763-772 (1998).
Kipriyanov, et al., “Bispecific diabody for lysis of human B-lineage leukemia cells”, The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology, p. 29 Thira Santorini, Greece (May 5-7, 1997).
Kipriyanov, et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics”,J. Mol. Biol., vol. 293, pp. 41-56 (1999).
Kostelny, “Formation of a Bispecific Antibody by the Use of Leucine Zippers”,J. of Immunology, vol. 148, No. 5, pp. 1547-1553 (1992).
Kufer et al., “Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.”,Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997.
Kumar et al., 3rdEdition, Clinical Medicine, pp. 369-370, Bailliere Tindall, (Exhibit 3), 1994.
Loffler, et al. “A Recombinant Bispecific Single-Chain Antibody, CD19 X CD3, Induces Rapid and High Lymphoma-directed Cytotoxicity by Unstimulated T Lymphocytes”,Blood, vol. 95, No. 6, pp. 2098-2103 (2000).
Mack et al., “Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3.”,Proceedings of the National Academy of Science, vol. 92, pp. 7021-7025, 1995, (Exhibit 6).
Mack, M., et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity”,Pro. Natl. Acad. Sci., vol. 92, pp. 7021-7025 (1995).
Olsen et al.,Hybridoma and Hybridomics, 22:65, 2003.
Pezzutto, et al., “CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-induced B Cell Activation and Proliferation”,J. of Immunology, vol. 138, No. 9, pp. 2793-2799 (1997).
Reusch, et al., “Effect of Tetravalent Bispecific CD19 X CD3 Recombinant Antibody Construct and CD28 Costimulation of Lysis of Malignant B Cells from Patients with Chronic Lymphocytic Leukemia by Autologous T Cells”,Int. J. Cancer, vol. 112, pp. 509-518 (2004).
Rudikoff, et al.,PNAS, 79:1979, 1982.
Schroder et al., “A Recombinant Bispecific Single Chain Antibody Cd19xcd3 Induced Rapid B Cell Lymphoma-Directed Cytotoxicity Of Unstimulated Human T Cells,” 40thAnnual Meeting Of The American Society Of Hematology Miami Beach, Florida, Dec. 4-8, 1998, XP-002115457, abstract.
Sompuram, et al.,The Journal of Immunology, 156: 1071-81, 1996.
Traunecker, et al. “Janusin: New Molecular Design fo
Bargou Ralf
Dorken Bernd
Kufer Peter
Loffler Anja
Lutterbuse Ralf
Foley & Lardner LLP
Harris Alana M.
Holleran Anne L
Micromet AG
LandOfFree
CD19xCD3 specific polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD19xCD3 specific polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD19xCD3 specific polypeptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101364